Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?
Authors:
- 18 June 2012
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 27 (1) , 226-232
Abstract
The concept of applying all active therapeutic agents in Total Therapy (TT) clinical trials for newly diagnosed multiple myeloma was pursued with the intent of developing curative treatment. The results of TT1 (n=231), TT2 (n=668) without or with thalidomide and TT3 with added bortezomib (n=303) have been reported. An update with median follow-up times of 17.1, 8.7 and 5.5 years, respectively, is provided. Conditional overall survival (OS) analysis from a 4-year landmark was applied to account for earlier protocol failure owing to disease aggressiveness and toxicities. Cumulative relative survival was computed in the context of age- and gender-matched US population, and interval-specific relative survival ratios were estimated to determine times to normal survival expectation. Based on Cox model-adjusted statistics, OS, progression-free survival and complete-response duration all improved with the transitions from TT1 to TT2 to TT3; improvement was also evident from time-to-progression estimates, 4-year conditional survival data and cumulative relative survival. Interval-specific relative survival normalized progressively sooner, reaching near-normal levels with TT3 in patients who attained complete response. Thus, a strategy using all myeloma-effective agents up-front seems effective at preventing, in progressively larger patient cohorts over time, the outgrowth of resistant tumor cells that account for ongoing relapses.Keywords
This publication has 51 references indexed in Scilit:
- Superior results of Total Therapy 3 (2003-33) in gene expression profiling–defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenanceBlood, 2010
- TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3British Journal of Haematology, 2009
- The molecular characterization and clinical management of multiple myeloma in the post-genome eraLeukemia, 2009
- Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survivalBlood, 2009
- Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high‐risk gene expression profileBritish Journal of Haematology, 2009
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosisBlood, 2006
- The molecular classification of multiple myelomaBlood, 2006
- Regression models for relative survivalStatistics in Medicine, 2003
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958